These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2702837)

  • 1. Monitoring versus interim analysis of clinical trials: a perspective from the pharmaceutical industry.
    Enas GG; Dornseif BE; Sampson CB; Rockhold FW; Wuu J
    Control Clin Trials; 1989 Mar; 10(1):57-70. PubMed ID: 2702837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach.
    Berry DA; Ho CH
    Biometrics; 1988 Mar; 44(1):219-27. PubMed ID: 3358990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.
    Williams GW; Davis RL; Getson AJ; Gould AL; Hwang IK; Matthews H; Shih WJ; Snapinn SM; Walton-Bowen KL
    Stat Med; 1993 Mar; 12(5-6):481-92. PubMed ID: 8493426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.
    Rockhold FW; Enas GG
    Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical decisions and the interim analyses of clinical trials.
    Stanev R
    Theor Med Bioeth; 2011 Feb; 32(1):61-74. PubMed ID: 21222041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data monitoring boards in the pharmaceutical industry.
    Herson J
    Stat Med; 1993 Mar; 12(5-6):555-61; discussion 563. PubMed ID: 8493431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General statistical design considerations of randomized clinical trials.
    Peduzzi P
    Prog Clin Biol Res; 1988; 264():61-70. PubMed ID: 3289035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials.
    Safer DJ
    J Nerv Ment Dis; 2002 Sep; 190(9):583-92. PubMed ID: 12357091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The test of public scrutiny.
    Mallinckrodt CH
    Pharm Stat; 2006; 5(4):249-52. PubMed ID: 17219626
    [No Abstract]   [Full Text] [Related]  

  • 10. A new futility test approach in clinical interim data monitoring.
    Xue D
    Pharm Stat; 2012; 11(6):468-75. PubMed ID: 23015479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early termination of clinical trials with prolonged observation of individual patients: a case study.
    van Es GA; Tijssen JG; Lubsen J; van Strik R
    Stat Med; 1987 Dec; 6(8):927-37. PubMed ID: 3438618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials.
    Matcham J; Julious S; Pyke S; O'Kelly M; Todd S; Seldrup J; Day S
    Pharm Stat; 2011; 10(1):70-3. PubMed ID: 20187020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Industry Perspective on Biomarker Development and Qualification.
    Gerlach CV; Derzi M; Ramaiah SK; Vaidya VS
    Clin Pharmacol Ther; 2018 Jan; 103(1):27-31. PubMed ID: 29143971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive design in clinical research: issues, opportunities, and recommendations.
    Chang M; Chow SC; Pong A
    J Biopharm Stat; 2006 May; 16(3):299-309; discussion 311-2. PubMed ID: 16724486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A safety monitoring procedure for a clinical drug development program, with application to the assessment of a novel COX-2 inhibitor.
    Bolland K; Whitehead J; Oldham M
    J Biopharm Stat; 2008; 18(4):737-49. PubMed ID: 18607805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coding of DNA samples and data in the pharmaceutical industry: current practices and future directions--perspective of the I-PWG.
    Franc MA; Cohen N; Warner AW; Shaw PM; Groenen P; Snapir A;
    Clin Pharmacol Ther; 2011 Apr; 89(4):537-45. PubMed ID: 21346752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical researchers and the pharmaceutical industry. Usefulness and need for an independent steering committee].
    Van Gijn J; Algra A
    Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1477-9. PubMed ID: 10443264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
    Xia HA; Ma H; Carlin BP
    J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.